Additionally, we observed a strong positive correlation between TMEM160 and NRF2 expression in GC, with patients co-overexpressing TMEM160 and NRF2 exhibiting poor prognosis and reduced therapeutic efficacy. The gene discussed is NFE2L2; the disease is gastric cancer.